Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Suzanah C. Boyd"'
Autor:
Gulietta M. Pupo, Suzanah C. Boyd, Carina Fung, Matteo S. Carlino, Alexander M. Menzies, Bernadette Pedersen, Peter Johansson, Nicholas K. Hayward, Richard F. Kefford, Richard A. Scolyer, Georgina V. Long, Helen Rizos
Publikováno v:
Biomarker Research, Vol 5, Iss 1, Pp 1-4 (2017)
Abstract Alternate BRAF splicing is the most common mechanism of acquired resistance to BRAF inhibitor treatment in melanoma. Recently, alternate BRAF exon 4–8 splicing was shown to involve an intronic mutation, located 51 nucleotides upstream of B
Externí odkaz:
https://doaj.org/article/84e147d5245d4efc8c430efe2b83f592
Autor:
Georgina V. Long, Richard A. Scolyer, Richard F. Kefford, John F. Thompson, Robyn Saw, Julie Howle, Suzanah C. Boyd, Therese M. Becker, Branka Mijatov, Lauren E. Haydu, Jessica Hyman, Carina Fung, Matteo S. Carlino, Gulietta M. Pupo, Alexander M. Menzies, Helen Rizos
PDF file - 197KB, Table S1 Exome sequencing data summary. Table S2 Candidate resistant variants identified in Prog melanomas. Table S3 Median MAPK activity scores of Pre-treatment versus Prog melanoma metastases and associated P-value. Table S4 Gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::691c31637feb577847ec995df5b0cc8b
https://doi.org/10.1158/1078-0432.22460846
https://doi.org/10.1158/1078-0432.22460846
Autor:
Helen Rizos, Georgina V. Long, Richard F. Kefford, Richard A. Scolyer, Adnan M. Nagrial, Mal Irvine, Suzanah C. Boyd, Jason R. Todd, Hamideh Shahheydari, Carina Fung, Matteo S. Carlino
Background: MEK1 mutations in melanoma can confer resistance to BRAF inhibitors, although preexisting MEK1P124 mutations do not preclude clinical responses. We sought to determine whether recurrent, preexisting MEK1P124 mutations affected clinical ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::110ab1548d00d020ff420f208f11de0c
https://doi.org/10.1158/1078-0432.c.6522786
https://doi.org/10.1158/1078-0432.c.6522786
Autor:
Georgina V. Long, Richard A. Scolyer, Richard F. Kefford, John F. Thompson, Robyn Saw, Julie Howle, Suzanah C. Boyd, Therese M. Becker, Branka Mijatov, Lauren E. Haydu, Jessica Hyman, Carina Fung, Matteo S. Carlino, Gulietta M. Pupo, Alexander M. Menzies, Helen Rizos
PDF file - 427KB, Figure S1 Identification of BRAFV600E splice variants in Prog tumor derived from Patient 9. Figure S2 Representative Sanger sequencing traces. Figure S3 Level of V600E BRAF allele relative to the wild type BRAF allele. Figure S4 Lin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c1242a121df90897c82fb32056b7bd8
https://doi.org/10.1158/1078-0432.22460849
https://doi.org/10.1158/1078-0432.22460849
Autor:
Helen Rizos, Georgina V. Long, Richard F. Kefford, Richard A. Scolyer, Adnan M. Nagrial, Mal Irvine, Suzanah C. Boyd, Jason R. Todd, Hamideh Shahheydari, Carina Fung, Matteo S. Carlino
Supplementary Figures 1-5. S1 MEK1 P124 variants activate ERK1/2; S2 MEK1P124Q diminishes BRAF inhibitor sensitivity; S3 Effect of MEK1 mutations on MAPK and PI3K pathway signaling; S4 Identification of MEK1P124Q variant in the SMU030 cell line; S5 C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::133911664742d3852007bcc120e15bbe
https://doi.org/10.1158/1078-0432.22454580.v1
https://doi.org/10.1158/1078-0432.22454580.v1
Autor:
Helen Rizos, Georgina V. Long, Richard F. Kefford, Richard A. Scolyer, Adnan M. Nagrial, Mal Irvine, Suzanah C. Boyd, Jason R. Todd, Hamideh Shahheydari, Carina Fung, Matteo S. Carlino
Supplementary Tables 1-5. S1 In silico evaluation of MEK1 Proline124 variants; S2 Correlation of factors and MEK1 mutation status; S3. Predictors of response to BRAF inhibition; S4. Univariate progression-free survival (PFS) according to MEK1 status;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::423c2fb6fefd7c59faccace81d0c0948
https://doi.org/10.1158/1078-0432.22454577
https://doi.org/10.1158/1078-0432.22454577
Autor:
Helen Rizos, Georgina V. Long, Richard F. Kefford, Richard A. Scolyer, Adnan M. Nagrial, Mal Irvine, Suzanah C. Boyd, Jason R. Todd, Hamideh Shahheydari, Carina Fung, Matteo S. Carlino
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a3623a9533a18ecfd0accdd3f57b114
https://doi.org/10.1158/1078-0432.22454586.v1
https://doi.org/10.1158/1078-0432.22454586.v1
Autor:
Carina Fung, Suzanah C. Boyd, Richard A. Scolyer, Peter Johansson, Gulietta M. Pupo, Richard F. Kefford, Nicholas K. Hayward, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long, Bernadette Pedersen, Helen Rizos
Publikováno v:
Biomarker Research, Vol 5, Iss 1, Pp 1-4 (2017)
Biomarker Research
Biomarker Research
Alternate BRAF splicing is the most common mechanism of acquired resistance to BRAF inhibitor treatment in melanoma. Recently, alternate BRAF exon 4–8 splicing was shown to involve an intronic mutation, located 51 nucleotides upstream of BRAF exon
Autor:
Suzanah C. Boyd, Richard F. Kefford, Mal Irvine, Bernadette Pedersen, Helen Rizos, Ashleigh Stewart
Publikováno v:
Oncogenesis, Vol 7, Iss 9, Pp 1-11 (2018)
Nearly all patients with BRAF-mutant melanoma will progress on BRAF inhibitor monotherapy and combination BRAF/MEK inhibitor therapy within the first year of therapy. In the vast majority of progressing melanomas, resistance occurs via the re-activat
Autor:
Richard A. Scolyer, Adnan Nagrial, Georgina V. Long, Hamideh Shahheydari, Carina Fung, Suzanah C. Boyd, Jason R. Todd, Mal Irvine, Helen Rizos, Richard F. Kefford, Matteo S. Carlino
Publikováno v:
Clinical Cancer Research. 21:98-105
Background: MEK1 mutations in melanoma can confer resistance to BRAF inhibitors, although preexisting MEK1P124 mutations do not preclude clinical responses. We sought to determine whether recurrent, preexisting MEK1P124 mutations affected clinical ou